The kidney, a cardiovascular risk marker, and a new target for therapy.
暂无分享,去创建一个
[1] E. Lewis,et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] M. Nieminen,et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.
[3] B. Dimitrov,et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. , 2004, Journal of the American Society of Nephrology : JASN.
[4] Hans L. Hillege,et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.
[5] D. de Zeeuw,et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. , 2004, Kidney international. Supplement.
[6] B. Brenner,et al. Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.
[7] Zhongxin Zhang,et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.
[8] B. Dimitrov,et al. Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results , 2004 .
[9] M. Nieminen,et al. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.
[10] S. Romundstad,et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] K. Iseki,et al. Proteinuria and the risk of developing end-stage renal disease. , 2003, Kidney international.
[12] D. Grobbee,et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.
[13] G. Eknoyan,et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] Hans L Hillege,et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.
[15] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[16] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .
[17] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[18] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[19] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[20] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[21] S. Yusuf,et al. Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.
[22] A. Charlesworth,et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.
[23] M. Schroll,et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. , 2000, Hypertension.
[24] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[25] M. Schroll,et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[26] W. Kannel,et al. The prognostic significance of proteinuria: the Framingham study. , 1984, American heart journal.
[27] C. Mogensen,et al. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. , 1984, The New England journal of medicine.